The MHRA has issued a drug alert on a patient-level recall of a brain tumour treatment.

Hospira UK is recalling certain batches of Temozolomide Hospira, usually supplied from hospitals and not in the community, due to reports of the capsules splitting and leaking their powder.

Pharmacists have been asked to: contact patients taking Temozolomide Hospira to provide advice on returning affected medicine; and quarantine any remaining stock, package it carefully and return it to Hospira for credit.

The affected batches are:

• L00828 5mg
• L00829 20mg
• L00831 100mg
• L01031 250mg

Patients who have affected medicine at home should: not open the pack; avoid contact with the powder on the skin, eyes and nose; and avoid inhaling the powder.

In the case of contact with the skin, patients should wash with soap and water; in the case of contact with the eyes and/or nose, wash with water only. If irritation persists, patients should seek medical advice.